Stan Berenshteyn
Stock Analyst at Wells Fargo
(1.21)
# 3,758
Out of 5,245 analysts
92
Total ratings
37.74%
Success rate
-14.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stan Berenshteyn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHR Phreesia | Downgrades: Equal-Weight | $15 → $9 | $8.92 | +0.90% | 3 | May 20, 2026 | |
| DOCS Doximity | Downgrades: Equal-Weight | $32 → $18 | $19.94 | -9.73% | 16 | May 14, 2026 | |
| OMDA Omada Health | Maintains: Equal-Weight | $17 → $18 | $16.51 | +9.02% | 2 | May 8, 2026 | |
| HNGE Hinge Health | Maintains: Overweight | $68 → $80 | $55.25 | +44.80% | 2 | May 6, 2026 | |
| OMCL Omnicell | Maintains: Overweight | $52 → $55 | $44.41 | +23.85% | 19 | Apr 23, 2026 | |
| CTEV Claritev | Maintains: Equal-Weight | $30 → $22 | $21.67 | +1.52% | 3 | Mar 19, 2026 | |
| HCAT Health Catalyst | Downgrades: Equal-Weight | $5 → $1 | $1.29 | -22.18% | 8 | Mar 18, 2026 | |
| VEEV Veeva Systems | Maintains: Overweight | $333 → $317 | $160.17 | +97.91% | 10 | Mar 5, 2026 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $7 → $3.5 | $2.64 | +32.58% | 9 | Mar 4, 2026 | |
| TDOC Teladoc Health | Maintains: Equal-Weight | $8 → $6 | $6.57 | -8.68% | 4 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $41 → $36 | $19.57 | +83.96% | 2 | Feb 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $9 | $7.96 | +13.07% | 5 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $125 | $88.11 | +41.87% | 9 | Feb 26, 2025 |
Phreesia
May 20, 2026
Downgrades: Equal-Weight
Price Target: $15 → $9
Current: $8.92
Upside: +0.90%
Doximity
May 14, 2026
Downgrades: Equal-Weight
Price Target: $32 → $18
Current: $19.94
Upside: -9.73%
Omada Health
May 8, 2026
Maintains: Equal-Weight
Price Target: $17 → $18
Current: $16.51
Upside: +9.02%
Hinge Health
May 6, 2026
Maintains: Overweight
Price Target: $68 → $80
Current: $55.25
Upside: +44.80%
Omnicell
Apr 23, 2026
Maintains: Overweight
Price Target: $52 → $55
Current: $44.41
Upside: +23.85%
Claritev
Mar 19, 2026
Maintains: Equal-Weight
Price Target: $30 → $22
Current: $21.67
Upside: +1.52%
Health Catalyst
Mar 18, 2026
Downgrades: Equal-Weight
Price Target: $5 → $1
Current: $1.29
Upside: -22.18%
Veeva Systems
Mar 5, 2026
Maintains: Overweight
Price Target: $333 → $317
Current: $160.17
Upside: +97.91%
GoodRx Holdings
Mar 4, 2026
Maintains: Overweight
Price Target: $7 → $3.5
Current: $2.64
Upside: +32.58%
Teladoc Health
Feb 26, 2026
Maintains: Equal-Weight
Price Target: $8 → $6
Current: $6.57
Upside: -8.68%
Feb 19, 2026
Maintains: Overweight
Price Target: $41 → $36
Current: $19.57
Upside: +83.96%
Nov 5, 2025
Maintains: Overweight
Price Target: $12 → $9
Current: $7.96
Upside: +13.07%
Feb 26, 2025
Maintains: Overweight
Price Target: $110 → $125
Current: $88.11
Upside: +41.87%